Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Draper Asset Management LLC

Draper Asset Management LLC lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNAGet Rating) by 3.2% in the second quarter, HoldingsChannel reports. The fund owned 2,057 shares of the company’s stock after selling 69 shares during the quarter. Moderna makes up about 0.3% of Draper Asset Management LLC’s portfolio, making the stock its 23rd largest position. Draper Asset Management LLC’s holdings in Moderna were worth $294,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Oliver Lagore Vanvalin Investment Group acquired a new position in Moderna during the first quarter worth approximately $30,000. Great Valley Advisor Group Inc. raised its position in shares of Moderna by 47.9% in the 2nd quarter. Great Valley Advisor Group Inc. now owns 4,160 shares of the company’s stock worth $595,000 after buying an additional 1,348 shares during the period. Private Advisor Group LLC boosted its holdings in Moderna by 9.4% in the second quarter. Private Advisor Group LLC now owns 22,672 shares of the company’s stock valued at $3,239,000 after acquiring an additional 1,940 shares during the last quarter. Rosenberg Matthew Hamilton grew its position in Moderna by 33.2% during the second quarter. Rosenberg Matthew Hamilton now owns 529 shares of the company’s stock valued at $79,000 after acquiring an additional 132 shares during the period. Finally, Aviva PLC increased its stake in Moderna by 101.0% during the first quarter. Aviva PLC now owns 109,705 shares of the company’s stock worth $18,898,000 after acquiring an additional 55,118 shares during the last quarter. 60.76% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on MRNA shares. Argus reduced their price objective on Moderna from $180.00 to $150.00 and set a “buy” rating on the stock in a research note on Wednesday, September 14th. Chardan Capital decreased their price objective on shares of Moderna from $188.00 to $186.00 and set a “buy” rating for the company in a research note on Monday, November 7th. Cowen cut their target price on shares of Moderna from $165.00 to $145.00 in a research note on Thursday, October 20th. The Goldman Sachs Group lifted their target price on shares of Moderna from $290.00 to $296.00 and gave the company a “buy” rating in a report on Thursday, October 13th. Finally, JPMorgan Chase & Co. lowered their price target on Moderna from $165.00 to $122.00 and set a “neutral” rating for the company in a report on Monday, October 24th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $176.93.

Insider Activity at Moderna

In other Moderna news, President Stephen Hoge sold 1,119 shares of the firm’s stock in a transaction on Monday, August 29th. The shares were sold at an average price of $135.81, for a total transaction of $151,971.39. Following the completion of the transaction, the president now directly owns 1,625,800 shares of the company’s stock, valued at approximately $220,799,898. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Moderna news, President Stephen Hoge sold 1,119 shares of the company’s stock in a transaction that occurred on Monday, August 29th. The stock was sold at an average price of $135.81, for a total transaction of $151,971.39. Following the sale, the president now owns 1,625,800 shares in the company, valued at $220,799,898. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Juan Andres sold 839 shares of the stock in a transaction that occurred on Monday, August 29th. The stock was sold at an average price of $135.81, for a total value of $113,944.59. Following the transaction, the insider now directly owns 11,566 shares in the company, valued at approximately $1,570,778.46. The disclosure for this sale can be found here. Insiders have sold 483,436 shares of company stock valued at $64,832,812 over the last ninety days. Corporate insiders own 17.30% of the company’s stock.

Moderna Stock Down 1.5 %

Shares of MRNA traded down $2.78 during trading on Thursday, reaching $176.81. The company’s stock had a trading volume of 2,311,841 shares, compared to its average volume of 4,704,397. Moderna, Inc. has a twelve month low of $115.03 and a twelve month high of $376.65. The company has a quick ratio of 1.80, a current ratio of 2.10 and a debt-to-equity ratio of 0.05. The company has a market cap of $67.93 billion, a price-to-earnings ratio of 6.40, a P/E/G ratio of 1.28 and a beta of 1.74. The company has a fifty day moving average of $143.11 and a two-hundred day moving average of $146.64.

Moderna Company Profile

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Featured Stories

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNAGet Rating).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.